Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - risperidone -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 6.25 mg - tablet, film coated - excipient ingredients: macrogol 400; magnesium stearate; lactose monohydrate; crospovidone; titanium dioxide; sucrose; polysorbate 80; povidone; colloidal anhydrous silica; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; polysorbate 80; lactose monohydrate; macrogol 400; povidone; sucrose; hypromellose; magnesium stearate; titanium dioxide - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 400; crospovidone; magnesium stearate; lactose monohydrate; polysorbate 80; colloidal anhydrous silica; hypromellose; povidone; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: crospovidone; titanium dioxide; magnesium stearate; macrogol 400; polysorbate 80; hypromellose; lactose monohydrate; povidone; colloidal anhydrous silica; sucrose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - carvedilol, quantity: 3.125 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; polysorbate 80; sucrose; colloidal anhydrous silica; macrogol 400; povidone; titanium dioxide; hypromellose - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease.,carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - quetiapine fumarate, quantity: 345.366 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; macrogol 400; titanium dioxide; calcium hydrogen phosphate dihydrate; sodium starch glycollate type a; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - quetiapine fumarate, quantity: 172.683 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; povidone; calcium hydrogen phosphate dihydrate; purified talc; microcrystalline cellulose; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - quetiapine fumarate, quantity: 115.122 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: purified talc; microcrystalline cellulose; lactose monohydrate; calcium hydrogen phosphate dihydrate; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate type a; povidone; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - quetiapine fumarate, quantity: 230.244 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; purified talc; povidone; lactose monohydrate; hypromellose; titanium dioxide; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia